Back to first-pass browser

First-pass extracted concept

microRNAs as Alzheimer's disease biomarkers and therapeutic targets

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

miRNA biomarkers, miRNAs, miRNA therapeutic targets

Extracted Explainers

What the tool is doing

The review describes miRNAs as dysregulated molecules in AD that may serve both as biomarkers and as therapeutic targets. Their expression patterns in biofluids and brain regions are presented as informative for diagnosis and disease staging.

Source 1DOIPubMed

Resources required

Translation to practice would require standardized measurement protocols, clinical-cohort validation, and cost-effective detection methods. Therapeutic use also requires targeted delivery approaches.

Source 1DOIPubMed

What problem it solves

miRNAs are presented as a way to improve early and non-invasive AD diagnosis while also enabling intervention across multiple disease-related pathways.

Source 1DOIPubMed

What it does not solve

The abstract states that heterogeneity, stability, and targeted delivery remain major obstacles, so miRNA-based approaches are not yet fully practical or validated for routine use.

Source 1DOIPubMed

Alternatives

The abstract contrasts miRNA approaches with existing diagnostic tools and suggests integration with those tools rather than outright replacement.

Source 1DOIPubMed

Evidence Snippets

MicroRNAs (miRNAs) ... show distinct dysregulation patterns in AD patients' blood, cerebrospinal fluid (CSF), and brain tissues ... offering potential as non-invasive diagnostic tools ... This review comprehensively examines the dual role of miRNAs as diagnostic biomarkers and therapeutic targets for AD.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1diagnostic potentialsupports2026Source 1DOIPubMed

miRNAs show distinct dysregulation patterns in blood, cerebrospinal fluid, and brain tissues of Alzheimer's disease patients.

Quoted textsource-backed
MicroRNAs (miRNAs) ... show distinct dysregulation patterns in AD patients' blood, cerebrospinal fluid (CSF), and brain tissues.
Claim 2limitationsupports2026Source 1DOIPubMed

miRNA heterogeneity, stability, and targeted delivery are major impediments to translating miRNA-based diagnostics and therapies for Alzheimer's disease.

Quoted textsource-backed
However, challenges, including miRNA heterogeneity, stability, and targeted delivery, remain critical impediments.
Claim 3mechanistic rolesupports2026Source 1DOIPubMed

miRNAs influence synaptic plasticity, mitochondrial function, and autophagy in the Alzheimer's disease context.

Quoted textsource-backed
miRNAs also influence synaptic plasticity, mitochondrial function, and autophagy, presenting multifaceted opportunities for intervention.
Claim 4mechanistic rolesupports2026Source 1DOIPubMed

miRNAs modulate Alzheimer's disease-related pathways including neuroinflammation via NF-κB signaling, amyloid-beta production through BACE1 inhibition, and tau phosphorylation via GSK3β regulation.

Quoted textsource-backed
Therapeutically, miRNAs modulate multiple AD-related pathways, including neuroinflammation via NF-κB signaling, Aβ production through BACE1 inhibition, and tau phosphorylation via GSK3β regulation.
Claim 5translation requirementsupports2026Source 1DOIPubMed

Standardized protocols, further validation in clinical cohorts, and cost-effective detection methods are needed to translate miRNA-based Alzheimer's diagnostics and therapies into practice.

Quoted textsource-backed
we underscore the need for standardized protocols, further validation in clinical cohorts, and the development of cost-effective detection methods to translate miRNA-based approaches into practical diagnostics and therapies.